Compare GILT & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILT | CSTL |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 722.8M |
| IPO Year | 1997 | 2019 |
| Metric | GILT | CSTL |
|---|---|---|
| Price | $10.02 | $33.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $19.00 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 580.1K | 389.6K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $15.06 | $2.42 |
| Revenue Next Year | $11.72 | $12.69 |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $9.50 | $17.72 |
| 52 Week High | $20.99 | $44.28 |
| Indicator | GILT | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 62.74 |
| Support Level | N/A | $22.88 |
| Resistance Level | $12.24 | $34.23 |
| Average True Range (ATR) | 0.35 | 1.64 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 19.78 | 78.24 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.